Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.41 |
| ▸ | CA2 | P00918 | 12/20 | 0.41 |
| ▸ | CA9 | Q16790 | 10/20 | 0.41 |
| ▸ | CA12 | O43570 | 9/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808429 | 0.77 | CA12 (0.33) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL4733933 | 0.71 | CA2 (0.61) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL7976910 | 0.70 | CA2 (0.47) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL4802122 | 0.70 | CA2 (0.55) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL30434205 | 0.70 | CA2 (0.64) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL30269780 | 0.70 | CA2 (0.59) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL30301831 | 0.69 | CA12 (0.57) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL3906957 | 0.67 | CA2 (0.64) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL28820908 | 0.67 | CA2 (0.55) | CA1CA2CA9CA12LRRK2 | |
| SCHEMBL2311184 | 0.66 | LRRK2 (0.56) | CA1CA2CA9CA12LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541498-B2 | Antiinflammatory agents, antiasthmatics | TEXAS BIOTECHNOLOGY | 2003-04-01 | — | — | US | disclosed |
| US-6376523-B1 | HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE | TEXAS BIOTECHNOLOGY CORPORATION | 2002-04-23 | — | — | US | disclosed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6030991-A | ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS | TEXAS BIOTECHNOLOGY CORP. (US) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | EDNRB, EDNRA, ECE1 | CA1 3550/4885CA2 1537/4885CA9 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.